Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-generation multicenter studies: using artificial intelligence to automatically process unstructured health records of patients with lung cancer across multiple institutions.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT).

Orphanet journal of rare diseases·2021
Same author

RMND1 mutations in two siblings: Severe renal hypoplasia but different levels of extrarenal abnormality severity: The ethics of decision making.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2019
Same author

Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group.

Molecular genetics and metabolism·2019
Same author

Transition from pediatric to adult care in adolescents with hereditary metabolic diseases: Specific guidelines from the French network for rare inherited metabolic diseases (G2M).

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2018
Same author

Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.

Orphanet journal of rare diseases·2017

Related Experiment Video

Updated: Jul 7, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

[Gaucher disease in childhood].

V Levrat1, I Forest, A Fouilhoux

  • 1Centre de référence des Maladies Héréditaires du Métabolisme, Hôpital Edouard Herriot, 5, place d'Arsonval, 69437 Lyon 03, France. virginie.levrat@chu-lyon.fr

La Revue De Medecine Interne
|January 30, 2008
PubMed
Summary

Gaucher disease is a pediatric condition, with most cases appearing before age 20. Neurological involvement significantly impacts treatment, prognosis, and genetic counseling for Gaucher disease patients.

Area of Science:

  • Pediatric Genetics
  • Rare Diseases
  • Neurology

Background:

  • Gaucher disease is often recognized in adults but predominantly affects children, with two-thirds of patients manifesting symptoms before age 20.
  • Three distinct clinical subtypes of Gaucher disease are recognized, primarily differentiated by the presence and severity of neurological involvement.
  • Early-onset Gaucher disease in childhood is a strong predictor of a severe and progressive clinical course.

Purpose of the Study:

  • To highlight Gaucher disease as a significant pediatric condition.
  • To differentiate the clinical presentations and implications of the three main Gaucher disease types.
  • To emphasize the impact of neurological involvement on disease management and counseling.

Main Methods:

  • Clinical review of Gaucher disease patient data.

More Related Videos

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review
05:06

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review

Published on: March 27, 2026

Related Experiment Videos

Last Updated: Jul 7, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review
05:06

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review

Published on: March 27, 2026

  • Classification of patients into three types based on neurological involvement.
  • Analysis of symptom onset, progression, and key clinical features.

    • Main Results:

    • Gaucher disease type 1 (non-neuronopathic) typically presents before age five with splenomegaly and frequent bone crises.
    • Gaucher disease type 2 (acute neuronopathic) begins in early infancy (3-6 months) and currently lacks specific treatment.
    • Gaucher disease type 3 (chronic neuronopathic) shares features with type 1 but includes progressive saccade-initiation failure and developmental delay.

    Conclusions:

    • Neurological symptoms in Gaucher disease have profound implications for treatment strategies, patient prognosis, and genetic counseling.
    • Recognizing Gaucher disease as a pediatric disorder is crucial for timely diagnosis and intervention.
    • The distinct clinical trajectories of Gaucher disease types necessitate tailored management approaches.